Purpose
The opportunity
Microsol is building seriously impressive tech to shake up the world of inhaled medicines.
As an aerosol technology startup, it is dedicated to accelerating and advancing the development of orally inhaled and nasal drug products.
Founded by Dr. Dan Hardy, they’ve developed a way to analyse aerosol particles at a microscopic level, helping pharma companies design better, smarter respiratory drugs at a fraction of the normal time.
Rationale
Why we invested
We liked the credibility and energy of the team as well as the purpose of cost and time saving for inhaled medicine development, accelerating the time to market for pharmaceutical companies.
We’re backing Microsol alongside the robust team at Zinc VC as part of their £500k pre-seed round. One of those startups that’s both properly deep tech and solving a real problem.
Future
Use of funds
The investments made will support Microsol through their next set of milestones to achieve further funding.
Microsol has a 18 month use of funds plan to develop and file initial formulation technology patents which target the respiratory delivery of biopharmaceutical drugs.
Around this, the company will grow with key technical hires and internal research infrastructure.
Real impact. Real startups
Related investments
Discover the startups our members are backing across the South West and South Wales. Explore recent investments and see the impact we’re making.
Ready to shape the future together?
Back the South West and South Wales’ most ambitious founders and grow your portfolio with us. Whether you’re new or experienced, Angel Investors Bristol gives you the network, insight, and opportunities to make real impact.
